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ABSTRACT: 
Cornelia de Lange Syndrome [CdLS (MIM#122470)] is a rare multisystemic disorder, 
characterized by a typical phenotype that includes distinctive facial dysmorphism, 
hirsutism, growth and psychomotor developmental delay, limb defects, multiple organ 
system problems such as frequent gastrointestinal and congenital heart defects. CdLS 
is essentially caused by defects in NIPBL and SMC1A genes (~50% and 5% of cases, 
respectively), but less frequently mutations have been also described in other genes 
(SMC3, HDCA8, RAD21). This genetic heterogeneity in CdLS is partially explained by 
a close functional relationship at the cellular level, since all these genes encode for 
proteins involved in the sister chromatid cohesion complex. The molecular and clinical 
characterization of CdLS patients was initiated at the national level in 2005. This initial 
part of the work enabled the detailed characterization of thirteen CdLS patients with 
novel NIPBL mutations, and the development of a locus specific database for this gene 
(Oliveira et al., 2010). 
The present work intended to unfold new molecular findings in the remaining 40 CdLS 
patients of our cohort. Molecularly unresolved patients were also analyzed by other 
techniques such as multiplex ligation-dependent probe amplification technique for 
NIPBL gene, and by high resolution melting curve analysis (hrMCA) for SMC1A. The 
analysis of NIPBL gene identified eight mutations previously reported in the literature 
(including a case with suspected somatic mosaicism), three novel mutations (c.86del, 
c.6983C>G and c.7307C>T) and two large deletions. The development of hrMCA 
applied to SMC1A is a fast and cost-effective scanning method, and allowed the 
identification of one mutation (c.1487G>A). 
Overall, mutations in SMC1A and NIPBL have been identified in 51% of the 
Portuguese CdLS patients studied by our group. The combination of different 
experimental procedure was essential for attaining an enhanced mutation detection 
rate in CdLS. Considering the distinct gene mutation detection rates a flowchart is 
proposed for the genetic molecular diagnostic of CdLS. Due to recent discovery of new 
genes involved in the disease, and considering that several patients are still 
molecularly uncharacterized, its plausible that in a near future new genetics causes for 
CdLS will be identified. 
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RESUMO: 
A Síndrome Cornélia de Lange [CdLS (MIM#122470)] é uma doença multissistémica 
rara, caracterizada por um fenótipo típico que inclui um dismorfismo facial 
característico, hirsutismo, atraso no crescimento e desenvolvimento psicomotor, 
defeitos nos membros, problemas associados a múltiplos sistemas de órgãos, sendo 
os mais frequentes problemas cardíacos, e refluxo gastrointestinal. A CdLS está 
associada a defeitos nos genes NIPBL e SMC1A genes (identificados em ~50% e 5% 
dos doentes, respectivamente), mas outras mutações mais raras foram descritos em 
outros genes (SMC3, HDCA8, RAD21). A heterogeneidade genética nesta síndrome é 
explicada ao nível celular, pela proximidade funcional das proteínas codificadas por 
estes genes, estando envolvidas no complexo das coesinas que unem os cromatídeos 
irmãos. Em 2005, iniciou-se em Portugal a caracterização clínica e molecular dos 
doentes com CdLS. A parte inicial deste projecto permitiu a descrição detalhada de 
treze doentes com novas mutações no gene NIPBL e o desenvolvimento de uma base 
de dados de mutações específica para este locus (Oliveira et al., 2010). 
Com a realização desta dissertação de mestrado pretende-se contribuir na 
caracterização molecular dos restantes 40 doentes Portugueses do grupo de estudo. 
Os casos não esclarecidos molecularmente foram analisados por outras técnicas 
nomeadamente, multiplex ligation-dependent probe amplification technique aplicada ao 
gene NIPBL, e por high resolution melting curve analysis (hrMCA) desenvolvida para o 
gene SMC1A. A análise do gene NIPBL permitiu a identificação de oito mutações 
anteriormente descritas na literatura (incluindo um caso com suspeita de mosaicismo 
somático), três novas mutações (c.86del, c.6983C>G e c.7307C>T), bem como duas 
grandes delecções neste gene. O desenvolvimento da técnica hrMCA aplicada ao 
gene SMC1A demonstrou ser eficaz, tratando-se de um método rápido e rentável, 
tendo permitido a identificação de uma mutação (c.1487G>A). 
Considerando todos os dados obtidos, foram identificadas mutações em 51% dos 
doentes Portugueses com CdLS. A utilização de diferentes técnicas moleculares foi 
essencial para atingir uma taxa de detecção de mutações mais elevada. Devido à 
recente descoberta de dois genes envolvidos na doença, (HDCA8, RAD21), e 
existindo ainda uma percentagem razoável de casos sem mutação identificada, é 
possível que novas causas genéticas de CdLS sejam identificadas neste doentes. 
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1. Introduction 
 
1.1. Cornelia de Lange Syndrome 
Cornelia de Lange Syndrome (CdLS) is a rare, multisystemic developmental 
disorder that can be characterized by a typical phenotype, although it can be highly 
variable between affected individuals, depending on the severity (Krantz et al., 2004). It 
has an estimated prevalence of about 1:10 000 individuals (Kline et al., 2007). 
However, since additional patients with milder CdLS phenotypes have been reported in 
the literature its actual incidence and prevalence may be more common than initially 
suspected. 
 
1.1.1. History and Nomenclature 
The first known description of CdLS was made by Vrolik in 1849, who reported a 
case as an extreme example of oligodactily (Oostra et al., 1994). In 1916, a German 
physician named Winfried Brachmann made a detailed description of a case of a 
patient that had died from pneumonia at 19 days of age, which presented CdLS 
features (symmetric monodactyly, antecubital webbing, dwarfism, cervical ribs, and 
hirsutism) (Deardorff et al., 2011; Johns et al., 2012). Seventeen years later, Cornelia 
Catharina de Lange, a Dutch pediatrician described two unrelated patients that shared 
similar features. Both cases had mental retardation, microcephaly and unusual facies 
that resembled each other. She described these cases in detail and proposed a 
diagnostic criteria, reporting these cases as typus degenerativus amstelodamensis 
(Amsterdam type degeneration), after the city that she worked in (de Lange 1933; 
Kumar et al., 1985).  
This syndrome is usually known as Cornelia de Lange Syndrome, honoring the 
pediatrician’s contribution to the characterization of the disorder, but can be also known 
as Brachmann de Lange syndrome, Amsterdam type degeneration or Amsterdam 
dwarfism (Johns et al., 2012). 
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1.1.2. Clinical features 
CdLS phenotype includes distinctive facial dysmorphic features, hirsutism, growth 
and psychomotor developmental delay, limb abnormalities, and relatively frequent 
gastrointestinal and congenital heart defects (Krantz et al., 2004; Tonkin et al., 2004). 
This syndrome is usually sporadic, but there are some familial occurrences reported in 
about 1% of cases (Lalatta et al., 2007). 
The characteristic dysmorphic facial features, are the most consistent and 
recognizable clinical findings in CdLS (Liu and Krantz, 2009). This include arched 
eyebrows with synophrys (and sometimes a severe ptosis), short neck, hirsute 
forehead, long and thick eyelashes, and a long and smooth philtrum (Kline et al., 2007). 
Ears may be lowset and posteriorly rotated, and the mid face flattened with depressed 
nasal bridge. The patients can also have upper thin lips, high palate, broadly spaced 
teeth and micrognatia (Liu and Krantz, 2009).  
Limb defects help to corroborate a CdLS diagnosis (Kline et al., 2007). These 
findings can range from small hands and feet, to severe anomalies of the upper limbs. 
The majority of CdLS cases can have brachydactyly and clinodactyly, a shorter first 
metacarpal, and proximally placed thumbs, while the most severe cases can have 
oligodactyly, ulnar deficiencies or absent forearms (Kline et al., 2007; Krantz et al., 
2004). 
Growth and developmental delay is usually observed, with patients having small 
stature, microcephaly, mental and/or learning disabilities, especially speech and 
language problems (Bork et al., 2004; Liu and Krantz, 2009).  
Multiple organ systems can be involved in CdLS, but the mostly affected include 
the gastrointestinal system (especially the presence of gastroesophageal reflux 
disease), hearing, genitourinary system, ocular system, heart and diaphragm. Besides 
limb defects other orthopedic complications may occur (Kline et al., 2007; Dorsettt and 
Krantz, 2009).  
Most patients have behavioral problems that can be caused or enhanced by the 
disease physical complications. Common behavioral and neurological problems that 
have been reported in CdLS patients include autistic behavior, self injurious tendencies, 
obsessive compulsive behavior, attention deficit disorder, and depression (Liu and 
Krantz, 2009). 
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 The variability of the CdLS phenotype expression been shown since the earliest 
reports of this syndrome. While the most severe cases of CdLS have many of the 
symptoms described above, in the mildest forms the patients usually have mild to 
moderate mental disability and (at least at a young age) typical facial characteristics, 
without other substantial structural differences. This implies that the brain is the most 
sensitive organ to this condition (Dorsettt and Krantz, 2009). This variation between 
affected individuals has led to the development of scoring systems that help to 
establish a genotype-phenotype correlation, and to anticipate care measures that will 
be needed by each patient (Kline et al., 2007).  
 
1.1.3. Etiology 
CdLS is a genetically heterogeneous syndrome since five genes have been 
reported as implicated in this disease. The majority of patients have de novo dominant 
mutations in NIPBL gene (40-60% of patients) (Russo et al., 2012). This explains the 
reason why the bulk of patients have a sporadic inheritance pattern and there are only 
a few familial cases. In addition, a limited number of patients have been described as 
having mutations in other genes such as SMC1A and SMC3 (~5% and <1% of patients 
respectively). All of these encode for proteins involved in the Cohesin sister chromatid 
cohesion (Galendari et al., 2011). 
 Very recently, another gene involved in the cohesion complex, HDAC8, has been 
reported as causing CdLS but mutations were identified in a very small percentage of 
patients (Deardorff et al., 2012a). A closely related gene, RAD21, has also been found 
to cause a cohesinopathy with several overlapping features with CdLS (Deardorff et al., 
2012b). Other unidentified genes are thought to be involved with this syndrome since 
many patients are still molecularly unresolved (Russo et al., 2012). Considering the 
importance of the cohesin complex to this syndrome, this subject will be covered in 
more detailed in the next section of this Introduction. 
 
1.2. Biochemistry basis of CdLS - the cohesin complex 
Cohesin complex has a crucial role in cell division by regulating sister chromatid 
cohesion during mitosis and meiosis. During the last years several studies have 
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demonstrated that this complex, together with their key regulators, has other essential 
functions during cell cycle progression. These include: i) DNA double strand repair in 
G2 phase, ii) gene expression by determining the amount of elongating RNA 
polymerases on genes (Fay et al., 2011) and thereby, iii) contributing for maintaining 
the genome’s stability (reviewed by Horsfield et al., 2012).  
During mitosis and meiosis cohesin complex is composed by several proteins 
(Figure 1.1 and Table 1.1). It comprises a heterodimer of SMC1A and SMC3, forming a 
“hinged” domain. This dimer interacts via the ATP-binding regions with α-kleisen 
subunit (RAD21), which subsequently interacts with Stromalin/SA subunit (known 
STAG), forming a ring-like structure (Hosfield et al., 2012). The prevailing theoretical 
model suggests that these molecular “rings” entrap sister chromatics by encircling DNA. 
A new layer of complexity is added to this model when considering that the cohesin’s 
“life-cycle” (turnover, recycling, loading and unloading onto chromosomes) is regulated 
by several molecular partners (Table 1.1). The loading of cohesin to DNA is controlled 
by NIPBL/MAU2 complex, whereas the opposite activity is mediated by a “releasin” 
(WAPAL/PDS5) which interacts with SA to open the ring structure. In humans, ESCO1 
and ESCO2, two cohesion acetyl transferases, are necessary for SMC3 acetylation 
(Hosfield et al., 2012). This step is necessary for adequate sister chromatid cohesion, 
since generates the “cohesive” form of cohesin. Interestingly, defects in ESCO2 are 
linked to another cohesinopathy, known as Roberts Syndrome (RBS, MIM#268300) 
(Vega et al., 2005). SMCs complexes can also be “recycled” and reloaded to chromatin 
after mitosis. An essential step for this recycling is the deacetylation of SMC3 by 
HDAC8, which is the opposite function of ESCO2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 –  Schematic representat ion of the cohesin complex during mitosis, 
showing the different core components and regulators (adapted from Horsfield et al., 
2012). 
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Table 1.1-  Members and regulators of the cohesin complex (proteins, genes and phenotypes ).  
#? - omim number is not available yet; CDLS- Cornelia de Lange Syndrome. 
 
Cohesin 
complex 
Protein Main function 
Gene, 
Locus, 
 MIM* 
Phenotype, 
MIM# 
Key references 
SMC 
subunits 
Structural maintenance 
of chromosomes 1A 
(SMC1A) 
Core cohesin 
subunit 
SMC1A , 
Xp11.22-p11.21, 
*300040 
CDLS2, 
#300590 
Sumara et al., 2000; 
Musio et al., 2006 
Structural maintenance 
of chromosomes 1B 
(SMC1B) 
Cohesin 
subunit 
(meiosis) 
SMC1B , 
22q13.31, 
*608685 
- 
Revenkova et al., 2001; 
Revenkova et al., 2004 
Structural maintenance 
of chromosomes 3 
(SMC3/CSPG6/ 
Bamacan) 
Core cohesin 
subunit 
SMC3 , 
10q25, 
*606062 
CDLS3, 
#610759 Sumara et al., 2000; 
Deardorff et al., 2007 
α-Kleisin 
subunit 
Homolog of RAD21  
S. pombe (RAD21) 
Core cohesin 
subunit 
RAD21, 
8q24, 
*606462 
 
CDLS4, 
#614701 Sadano et al., 2000; 
Deardorff et al., 2012b 
Homolog of REC8 
S. pombe (REC8) 
Cohesin 
subunit 
(meiosis) 
REC8, 
14q11.2-q12, 
*608193 
- 
Parisi et al., 1999 
Stromalin/ 
SA subunit 
Stromalin antigen 1 
(STAG1/SA1/SCC3A) 
Cohesin 
subunit 
STAG1 , 
3q22.3, 
*604358 
- 
Carramolino et al., 1997; 
Sumara et al., 2000 
Stromalin antigen 2 
(STAG2/SA2/SCC3B) 
STAG2, 
 Xq25, 
 *300826 
- 
Carramolino et al., 1997 
Sumara et al., 2000 
Stromalin 3 
(STAG3/SA3) 
Cohesin 
subunit 
(meiosis) 
STAG3,  
7q22.1, 
*608489 
- 
Pezzi et al., 2000 
Interactors 
of α-kleisin 
and SA 
Homolog of  PDS5A, 
regulator of cohesion 
maintenance A 
S. cerevisiae  ( PDS5A) 
Balancing 
cohesion 
establishment 
with cohesin 
dissociation 
PDS5A, 
4p14, 
 *613200 
- 
Kumar et al. 2004 ; 
Zhang et al., 2009 
Homolog of  PDS5B, 
regulator of cohesion 
maintenance B 
S. cerevisiae  
(PDS5B/APRIN/AS3) 
PDS5B, 
13q12.3, 
*605333 
- 
Geck et al., 2000; 
Zhang et al., 2009 
Cell division cycle-
associated protein 5 
(CDCA5/SORORIN) 
CDCA5, 
11q12.1, 
*609374 
- 
Rankin et al., 2005; 
Nishiyama et al., 2010  
Homolog of wings apart-
like protein Drosophila 
(WAPAL/WAPL) 
WAPAL, 
10q23.2, 
*610754 
- 
Kueng et al., 2006; 
Nishiyama et al., 2010; 
Kollerin Nipped-B-like 
(NIPBL/SCC2/ 
DELANGIN) 
Cohesin 
loading 
NIPBL, 
5p13.2, 
*608667 
CDLS1, 
#122470 
Tonkin et al., 2004; 
Krantz et al., 2004 
 
Homolog of MAU2 
chromatid cohesion 
factor C. elegans 
(MAU2/SCC4) 
MAU2, 
19p13.11, 
*614560 
- 
Watrin et al., 2006 
Cohesin 
acetyl 
transferase 
Homolog of 
establishment of 
cohesion 1 S. cerevisiae 
(ESCO1) 
Establishment 
of cohesion 
ESCO1, 
18q11.2, 
*609674 
 
- 
Hou and Zou, 2005; 
Zhang et al., 2008 
Homolog of 
establishment of 
cohesion 2 S. cerevisiae 
(ESCO2) 
ESCO2, 
8p21.1, 
*609353 
 
Roberts 
syndrome, 
#268300 
SC phocomelia 
syndrome, 
#269000 
Hou and Zou, 2005; 
Vega et al., 2005; 
Gordillo et al., 2008 
Cohesin 
deacetylase 
Histone deacetylase 8 
(HDAC8) 
Recycling of 
cohesin 
HDAC8 , 
Xq13, 
*300269 
CDLS 
#? 
Buggy et al., 2000; 
van den Wyngaert et al., 
2000; 
Deardorff et al., 2012a 
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1.3. Genetics of CdLS 
1.3.1. NIPBL gene 
It was in 2004 that NIPBL (MIM*608667), the first gene responsible for CdLS was 
found by two independent groups (Krantz et al., 2004; Tonkin et al., 2004). This gene 
was found through genome-wide linkage exclusion analysis in affected families, in 
patients with de novo translocations and deletions, that allowed the identification of a 
candidate genomic region for CdLS. Using distinct approaches both works identified 
mutations in a gene named as NIPBL (Nipped-B like, MIM*608667) as causative of the 
disease (Krantz et al., 2004; Tonkin et al., 2004).  
The human NIPBL gene is located in chromosome 5, (5p13.1) and spans over 
190Kbp. The open reading frame (ORF) of NIPBL starts in exon 2, and continues to 
exon 47 (Tonkin et al., 2004). This gene encodes for delangin, a protein which contains 
a highly conserved armadillo domain with several HEAT-repeats, a protein-protein 
interaction motif (Selicorni et al., 2008), a glutamine-rich domain, and a predicted 
bipartite nuclear localization signal (Yan et al., 2006; Braunholz et al., 2012). This 
protein has two isoforms: delangin-A (the mainly expressed form), a long form with 
2804 amino acids, and delangin-B, the shorter form with 2697 amino acids (Tonkin et 
al., 2004). It is involved in cohesin complex loading, mediating chromatin modifications 
through recruitment of histone deacetylases. NIPBL was identified as the human 
homologue of Drosophila melanogaster Nipped-B gene, a chromosomal adherin 
involved in chromatid cohesion and also acting as a transcriptional regulator in Yeast 
(SCC2) (Bhuiyan et al., 2006). Further studies have demonstrated that the human 
protein is a regulator of the cohesin complex required for binding of the cohesin 
complex (Braunholz et al., 2012; Dorsett et al., 2007). NIPBL-mutated cells from CdLS 
patients have shown a reduced capacity to tolerate DNA damage (Revenkova et al., 
2009). 
Nearly half of CdLS cases are caused by mutations in NIPBL gene, being the 
major causative gene for this syndrome. Mutations in this gene can cause mild to 
severe forms of the disease (Galendari et al., 2011). Genotype-phenotype correlations 
studies indicate that severe NIPBL mutations (originating premature termination 
codons) usually cause more severe forms than missense mutations (Dorsettt and 
Krantz, 2009).  
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In 2010, Oliveira et al., reported the creation of a locus specific database (LSDB) 
for the NIPBL gene, which contained mutational and clinical data reported in all peer 
review papers. An analysis of the mutations in the database was made, and all 
mutations types were found in NIPBL: small deletions (27.6% of cases), missense 
changes (21.1%), nonsense mutations (17.3%), mutations affecting splicing (17.1%), 
small duplications (13.6%), insertions (1.5%) and insertion/deletions (1.5%). Statistical 
analysis suggested that patients with nonsense mutations or out-of-frame 
deletions/duplications/insertions more often presented a severe phenotype than those 
with less detrimental effect on the protein (Oliveira et al., 2010).  
The mutations in NIPBL seem to be spread all over the gene, without a clear 
hotspot. However, the authors have shown that mutation frequencies vary throughout 
the gene, meaning that some gene regions seem to be more prone to mutations than 
others (Figure 1.2). Gross genomic duplications or deletions in NIPBL gene are 
considered rare, and there were only a limited number of studies concerning their 
occurrence (Bhuiyan et al., 2007; Russo et al., 2012).  
 
Figure 1.2  –  NIPBL-LOVD database content analysis, showing the distribut ion of mutat ions and 
their frequency. Adapted from Oliveira et al.  (2010).  
 
1.3.2. SMC1A gene 
After the identification of NIPBL as a causative gene for CdLS, it was realized that 
mutations in this gene are only present in about half the patients. This mutation 
detection rate suggested that there could be other genes involved with this syndrome. 
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The variability of the clinical findings between patients also supported this hypothesis. 
Since NIPBL is involved in the cohesion complex, other genes encoding proteins linked 
to the cohesion complex were studied in patients with CdLS or CdLS-like phenotype.  
In 2006, mutations in the SMC1A gene (structural maintenance of chromosomes 
1A, MIM #300590) was found to cause an X-linked form of CdLS patients (Musio et al., 
2006). Mutations were found in three affected males of the same family and in an 
unrelated patient, without NIPBL mutations (Musio et al., 2006). The SMC1A gene is 
located in chromosome Xp11.22, with a size of 48Kbp, and has 25 exons (all of them 
coding). The SMC1A gene encodes for a protein with 1233 aminoacids, which is one of 
the four subunits of the cohesion complex. It is involved in genome stability and DNA 
repair (Musio et al., 2006; Watrin and Peters, 2006). Interestingly, the majority of 
patients with SMC1A mutations are females (Deardorff et al., 2007). While in normal 
females the SMC1A gene escapes X-inactivation and both copies are expressed, 
males are hemizygous for SMC1A since it is not located in the pseudoautosomal 
region. Affected females should express a normal copy of the gene, leading to the 
suggestion that SMC1A mutations are dominant-negative (Liu and Krantz, 2009; 
Hoppman-Chaney et al., 2011). 
X-linked CdLS patients seem to have a milder phenotype than the “classic” form, 
especially the female patients, having a milder dysmorphism, and a mild or no growth 
delay, and absence of microcephaly (Musio et al., 2006; Bork et al., 2007). Less severe 
cases result in a phenotype that approaches that of apparently nonsyndromic mental 
retardation (Revenkova et al., 2009), although severe phenotypes in this gene have 
also been reported (Hoppman-Chaney et al., 2011). Male patients seem to have a 
severer phenotype than females, more similar with a “typical” CdLS. (Musio et al., 
2006; Maninni et al., 2010). 
A LSDB for SMC1A gene was also developed (Oliveira et al., 2010). Most 
mutations reported were substitutions (~84%), and the remaining are small deletions 
(~16%). The majority of the mutations reported in this database have a de novo origin. 
The mutations appear spread over the gene, without a clear mutational hotspot 
(http://www.lovd.nl/SMC1A, last accessed 15 September 2012).  
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1.3.3. SMC3 gene 
The discovery that mutations in the X-linked SMC1A gene result in CdLS 
suggested that other members of the cohesin complex may contribute to the etiology of 
CdLS. In 2007, Deardorff and collaborators screened 115 CdLS patients that were 
negative for mutations in NIPBL, for mutations in genes encoding for subunits of the 
cohesin complex (SMC1A and SMC3). There was only one mutation found in SMC3 
gene so far, in two unrelated patients. It is a small deletion in exon 9 that results in the 
loss of a single amino acid. (Deardorff et al., 2007; Revenkova et al., 2009). 
The SMC3 gene (MIM#610759), or structural maintenance of chromosomes 3, is 
located on chromosome 10q25.2, and it has a size of 37Kbp, and 29 exons (all of them 
coding). This gene encodes for the SMC3 protein, with 1217 aminoacids, and like 
SMC1A, is one of the subunits of the cohesion complex (Deardorff et al., 2007; 
Revenkova et al., 2009). Patients with mutations in SMC3 present a mild variant of the 
CdLS phenotype, with very mild facial features, and no absence or reduction of limbs 
or digits, and no other major structural anomalies in contrast to classical CdLS 
phenotype (Deardorff et al., 2007). 
 
1.3.4. HDAC8 gene 
The involvement of HDAC8 in CdLS was discovered very recently by Deardorff and 
co-workers (2012a). His group characterized this gene product as a SMC3 deacetylase, 
and also detected six loss-of-function mutations in HDAC8 (Deardorff et al., 2012a). 
 The HDAC8 gene (MIM#601639), or histone deacetylase 8, is located in 
chromosome Xq13.1, has a size of 243.6 Kbp, and contains a total of 61 exons. In the 
cohesion complex, the HDAC8 protein is the SMC3 deacetylase. The SMC3 protein is 
acetylated by ESCO2 during S-phase to establish cohesiveness of chromatin-loaded 
cohesion, and HDAC8 protein deacetylates SMC3 during anaphase. The loss of 
HDAC8 activity in increased SMC3 acetylation and inefficient dissolution of the ‘used’ 
cohesin complex released from chromatin in both prophase and anaphase. Deardorff 
and team suggested that this defects lead to impaired embryonic development which 
can give rise to CdLS. (Deardorff et al., 2012a). 
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2. Objectives  
The molecular and clinical characterization of CdLS patients was initiated at the 
national level in 2005 with the research project entitled: “Caracterização clínica, 
epidemiológica e molecular dos doentes com o Síndrome de Cornelia de Lange em 
Portugal”, supported by the Instituto de Genética Médica Dr. Jacinto Magalhães. Our 
team of molecular and clinical geneticists gathered mutational and clinical data on a 
total of 53 Portuguese CdLS patients (this includes more recent cases). Thirteen of 
those patients, with novel NIPBL mutations, were initially reported together with the 
development of a LSDB (Oliveira et al., 2010). The present work intended to unfold 
new molecular findings in the remaining Portuguese CdLS patients. In brief, the main 
objectives of the present work were the following: 
i) Report the molecular characterization of the remaining CdLS patients with 
NIPBL mutations. 
ii) Apply Multiplex Ligation-dependent Probe Amplification technique (for 
NIPBL) in the group of CdLS patients that remained molecularly unresolved 
after NIPBL gene sequencing. 
iii) Set up a fast and cost-effective screening method for point mutations in 
SMC1A gene by High resolution melting curve analysis. 
iv) Optimize the molecular diagnostic procedure of CdLS patients. 
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3. Materials and Methods 
 
3.1. Patients 
Forty CdLS Patients were included in this work, recruited in two distinct phases: 
i) Research project (2005-2010). 
The criteria for inclusion were a diagnosis of CdLS confirmed by a clinical 
geneticist, a normal karyotype and guardian informed consent. A clinical protocol 
designed for a previous study (Dias et al., 2008) was used by clinical geneticists to 
assess the patients. This protocol includes information on prenatal, birth and postnatal 
history, an evaluation of 50 phenotypical features, behavior, development and 
multisystem involvement. A diagnostic severity score was also included in the protocol 
formulary. This scoring system described by Kline and collaborators (2007), classifies 
CdLS patients as mild, moderate or severe, according to the number and type of 
abnormalities (Annex I). From the 53 patients (from 51 different families) initially 
referred, 26 patients were recruited for this work. Fourteen were excluded for one of 
the following criteria: insufficient DNA for analysis (deceased patients, n=2), insufficient 
clinical data (incomplete/lacking clinical protocol information, n=2), patients with low 
severity score (with “Cornelia-like” features but not reaching the mild phenotype, n=10). 
Thirteen of these patients (from 12 different families) were previously published by our 
group (Oliveira et al., 2010) and thus, will not be included in the results section of this 
work. 
ii) Clinical requests for CdLS molecular studies (2010-2012). 
Fourteen new CdLS cases were referred for molecular studies. Together with the 
biological samples a specific request form was used to collect as most as possible 
information concerning their phenotype. The clinical classification of patients was 
based on the information retrieved from this test request form and was validated by a 
clinical geneticist using the score system proposed by Kline et al. (2007). 
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3.2. Preparation of biological samples 
3.2.1. DNA extraction method 
Genomic DNA (gDNA) was extracted from peripheral blood samples, collected 
from the patients and available parents in EDTA anticoagulant tubes, using salting out 
method (Miller et al., 1988). Since this method does not requires the use of toxic 
chemicals it is a good alternative to the phenol/chloroform extraction. Salting-out is 
based on the principle that proteins and other cellular contaminants are less soluble at 
higher salt concentrations due to their relative hidrophobicity and will precipitate in a 
saturated salt solution while the DNA does not. 
 
3.2.2. RNA extraction method 
One of the major concerns in manipulating RNAs, are the ribonuclease enzymes 
present in cells and tissues that can rapidly destroy these nucleic acids. Thus, it is 
important to avoid sample contamination with ribonucleases. Nuclease-free pipette tips 
and reagents were used and all micropipettes (used exclusive for RNA extraction), 
were cleaned with RNase AWAY™ (Life Technologies, Foster City, CA, USA). Total 
mRNA purification was made from peripheral blood sample in EDTA anticoagulant tube, 
using the commercial kit PerfectPure™ RNA Purification System (5 PRIME, Hamburg, 
Germany) following the manufacturer protocol. 
 
3.2.3. Nucleic acid quantification 
After the nucleic acid extraction, purity and concentration were determined through 
spectrophotometric absorbances at the wavelengths of 260 nm (A260) and 280 nm 
(A280).  A 2 µl sample was quantified in a Nanodrop spectophtometer (Thermo 
Scientific), with two independent measures. A260 is used to measure DNA (1U A260 = 
50 ng/μl) and RNA (1U A260 = 40 ng/μl) concentrations, while A280 is used to 
measure protein concentration. The A260/A280 ratio is used to determine the purity of 
nucleic acids. A pure DNA and RNA sample would have a ratio of ~1.8 and ~2.0 
respectively, while a protein contaminated sample has a lower ratio (Maniatis et al., 
1982) (Glasel, 1995).  
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3.2.4. RNA conversion to cDNA 
Since RNA is so easily degraded, it was more convenient to convert it to cDNA 
(complementary DNA). The High-Capacity cDNA Archive Kit (Life Technologies, Foster 
City, CA, USA) was used for the conversion, following the manufacturer protocol. This 
was made through a reverse transcription reaction (RT reaction), using MultiScribe™ 
Reverse Transcriptase (Life Technologies, Foster City, CA, USA) enzyme, and random 
(examer) primers. The RNA template was mixed with the kit reagent mixture, and 
placed in a thermocycler, and placed 10 minutes at 25ºC and 120 minutes at 37ºC. 
 
3.2.5. Aliquots preparation 
The gDNA samples were aliquoted at 100 μg/ml and 50 μg/ml concentrations for 
PCR (section 3.3), and for high resolution melting curve analysis (hrMCA) (section 3.8) 
use, respectively. This step was essentially done to preserve the original stock sample 
for future analysis, and to set the same gDNA concentration between all samples. This 
is not only useful to optimize the PCR but also critical for MLPA (section 3.6) and 
hrMCA techniques by prevent bias and allowing accurate results. The aliquots and 
original samples were stored at 4ºC until use, thus avoiding freeze-thaw of the samples 
at lower temperatures). 
 
3.3. DNA amplification by PCR 
The polymerase chain reaction (PCR) is an in vitro technique used in molecular 
biology, to amplify a target sequence (amplicon) of DNA exponentially.  Besides the 
DNA template being amplified, the PCR mixture needs several components, including:  
 Oligonucleotide sequences (primer pair) with a sequence complementary to 
the 3' (3 prime) ends of each of the sense and anti-sense strand of the DNA 
target region. 
 Deoxynucleotide triphosphates - dATP, dCTP, dGTP and dTTP (dNTPs).  
 DNA polymerase, (such as the thermostable Taq polymerase). 
FCUP 
Further contributions towards the molecular analysis of NIPBL and SMC1A genes in a cohort of 
patients with Cornelia de Lange Syndrome 
14 
 
 
 Buffer solution that enables the suitable activity and stability of the DNA 
polymerase. 
 Divalent cations (like Mg2+) and monovalent cation (like K+). 
This technique consists of cycles of: denaturation (separation of double strand 
DNA into single stranded DNA), annealing (primers pair with DNA complementary 
sequence), and extension (enzymatic replication of the DNA). This is done by 
repeatedly heating and cooling the reaction mixture. The DNA polymerase uses a 
single DNA strand to create a new complementary DNA strand in the site targeted by 
the pair of primers. The new DNA is itself used as a template for replication, creating a 
chain reaction in which the DNA template is exponentially amplified. Besides the cycle 
phase, there are some PCR programs that use a preliminary first denaturing step, 
heating the sample for heat-activated enzymes, or to help denature the target DNA 
better. A final extension (or final elongation) step can also be used to make sure that 
the single-stranded DNA is entirely extended (Maniatis et al., 1982). 
 
3.3.1. Oligonucleotides design 
Primer design is a critical step for a successful PCR approach. When designing 
primers several parameters should be considered (Burpo, 2001): 
 The primer sequences should be unique to target only a region of DNA, and 
avoid annealing at a similar sequence. 
 Primers with long repeats of a single nucleotide should be avoided (loop 
formations can occur). 
 Primers should not anneal with other primers or themselves (formation of 
primer dimers could contaminate the sample). 
 Primers should be located at least 30-40 bases upstream of the region of 
interest in the sequence read. 
 Optimal primer GC content between 40-60%  
 
NIPBL gene 
The mainly expressed isoform of the NIPBL gene (transcript with the accession 
number NM_133433.3) has a total of 47 exons, 46 of which are coding (exon 1 is non-
coding). A total of fifty-four primer pairs were used to completely cover the coding and 
flanking regions of the gene. In addition to the primers described by Krantz et al. (2004), 
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used for exon 10 and exons 39 to 47 of NIPBL gene, custom primers were designed for 
the remaining gene regions (exons 2 to 9 and 11 to 38, Annex II.a). 
 
SMC1A gene 
According to the transcript with accession number NM_006306.2, SMC1A gene 
has a total of 25 exons. Twenty six primer pairs were designed and used to cover the 
coding and flanking intronic regions of the gene (Annex II.b). The primers designed 
were optimized for hrMCA technique, with smaller amplicons, and without M13 
universal tail. 
Primer Express (Life Technologies, Foster City, CA, USA) software was used for 
primer design. Besides speeding up this process the application allowed to 
standardization of experimental conditions. Primers were chosen to have the same 
annealing temperature (58-60ºC). In the case of NIPBL gene approach primers 
incorporated a M13 universal primers tail sequence. Since the M13-tailed sequences 
are not present in the Human genome, primers are not fully complementary (at their 5’). 
These M13 universal primers are useful for downstream applications (such as Sanger 
sequencing) since the same sequencing primer can be used for all amplicons. In order 
to exclude primers more susceptible to primer-dimer formation, Fast PCR software 
(Kalendar and Schulman, 2009) was used. Finally, primer-BLAST (Ye et al., 2012, 
accessed at http://www.ncbi.nlm.nih.gov/tools/primer-blast/) algorithm was used to 
check for primer specificity. 
 
 
3.3.2. PCR mixture and thermocycling profiles 
The NIPBL PCR mixture (for all primer pairs) was prepared with the following 
reagents: 
10 μl of PCR Master Mix 2x (Cat No # M7505, Promega, Fitchburg, WI, USA) 
7 μl dH2O (nuclease free) 
1 μl Forward Primer + 1 μl Reverse Primer (primers at 10 pmol/μl) 
1 μl gDNA (100 ng/l) 
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Then, the PCR mixture samples were homogenized and placed in a thermocycler 
(Veriti® Thermal Cycler 96-well, Life Technologies, Foster City, CA, USA), to run one of 
the NIPBL programs.  
While all the other exons use the same PCR program (Table 3.1) with only 
differences in annealing temperatures, exon 44 primer pair had to be performed using 
a different thermocycler profile. This is mainly due to the particular base pair 
composition of this amplicon, which is particular prone to nonspecific amplification and 
a high background. Also, it was difficult to find a new alternative primer pair. To 
overcome this problem, a Touchdown PCR program (Table 3.2) was used for exon 44. 
This particular type of PCR increases the specificity of primer annealing by initiating at 
with higher annealing temperatures and by gradually reducing it. Higher temperatures 
result in greater specificity for the binding between the primer and the targeted DNA 
template, but low amplification yield. As cycle-by-cycle the annealing temperature 
lowers resulting in less specificity but increasing the efficiency of amplification. Due to 
the exponential amplification nature of PCR, the amplified (specific) sequences during 
the first cycles will out-compete the nonspecific sequences that may be result at lower 
temperatures. 
Table 3.1:  PCR program for NIPBL  ampli f icat ion  (except for exon 44)  
Step Temperature (ºC) Time Number of cycles 
initialization 94 5 min 1 
denaturing 
annealing 
expansion 
94 
Ta
 
72 
30 sec 
30 sec 
45 sec 
38 
 
final extension 72 10 min 1 
final hold 15 - - 
Ta - annealing temperature: for the custom primers and primers 10A, 40, 42, and 
45 to 47B, the annealing temperature was 58ºC. For the primers 10B to 10F and 39 
the annealing temperature was 55ºC, for the primer pair 43, the annealing temperature 
was 52ºC.  
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Table 3.2 :  Touchdown PCR program for NIPBL  exon 44 
Step Temperature (ºC) Time Number of cycles 
initialization 94 5 min 1 
denaturing 
annealing 
expansion 
94 
62 → 54 * 
72 
30 sec 
30 sec 
45 sec 
10 
 
denaturing 
annealing 
expansion 
94 
54 
72 
30 sec 
30 sec 
45 sec 
25 
 
final extension 72 10 min 1 
final hold 15 - - 
*  -0.8ºC each cycle, starting on the second cycle 
 
3.4.  Agarose gel electrophoresis 
After PCR amplification PCR products were analyzed by agarose gel 
electrophoresis. Gel electrophoresis is a way to separate and analyze DNA. It can be 
used to quantify or even to isolate a particular DNA fragment. An electric field causes 
negatively charged DNA molecules to travel through the agarose gel. DNA molecules 
must move through the matrix pores of the gel allowing their efficient separation 
according to size (being easier for the smaller molecules to migrate than the larger 
ones). To verify the PCR amplification 3 μl of each PCR sample product were mixed 
with 1 μl loading buffer (custom made) and loaded in 1% (m/v) SeaKem® LE Agarose 
(Cambrex Bio Science, Verviers, Belgium) gel stained with GelRed™ (Biotium, 
Hayward, CA, USA). A DNA low mass ladder (Life Technologies, Foster City, CA, 
USA) was also loaded in a separate lane of the gel to calculate the size to the DNA 
fragments. After running electrophoresis the gel was analyzed under UV light and 
images were obtained using a LAS-3000 image system (Fujifilm, Tokyo, Japan). 
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3.5.  PCR purification 
The PCR product was purified using the ExoSAP-IT® (Affimetrix, Santa Clara, CA, 
USA) enzymatic treatment. ExoSAP-IT® is a mixture of shrimp alkaline phosphatase 
and exonuclease that degrade primers and dephosphorylate dNTPs, improving the 
quality of the sequences resulting from PCR product. 
In this procedure 2 μl of ExoSAP-IT® was added to 8 μl of PCR product (for each 
amplicon) and this mixture was placed for 30 minutes at 37ºC followed by 15 minutes 
at 85ºC (enzyme inactivation step). 
 
3.6. Sanger Sequencing 
Purified PCR products were sequenced by dye-terminator cycle sequencing. In this 
type of sequencing, there are 4 (one for each base) chain terminator ddNTPs 
(dideoxynucleotide-tri-phosphate) tagged with fluorescent dyes that emit light in 
different wavelengths. These ddNTPs are mixed in lower concentration with dNTPs 
and when a DNA polymerase incorporates a ddNTP instead of a dNTP the chain 
extension is prematurely ended. This will produce a series of DNA fragments with 
different lengths that are terminated with a specific base. Cycle sequencing products 
must be cleaned of primers, excess dNTP’s, enzymes and buffer components before 
proceeding for electrophoresis. Currently this analysis is carried out in multi-capillary 
automated sequencers that can efficiently analyze several samples at the same time. 
Briefly, samples are injected into the capillaries loaded with a special polymer (used as 
a separation matrix) by means of an electric potential difference. This capillary 
electrophoresis resolves each dye labeled DNA fragments with high efficiency (1 bp 
difference). At the end of the capillary a laser-induced fluorescent system is used to 
excite each fluorochrome and the resulting light is detected. Finally the software 
converts all the fluorescence signals into an electropherogram. 
 
3.6.1. Sequencing reaction 
This sequencing reaction is an asymmetric PCR carried out using only one primer, 
resulting in the amplification of only one DNA strand of the double-stranded DNA 
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template. This means that to sequence both DNA strands two independent sequencing 
reactions are needed for each amplicon (one for each of the primer pair).  
Sequencing reactions were prepared with BigDye® Terminator Cycle Sequencing 
Kit v1.1 (Life Technologies, Foster City, CA, USA), using a mixture of 2 μl big-dye, 2 μl 
dH2O, 1 μl primer (at 5 pmol/μl) and 5 μl purified PCR products. The M13 Universal 
primers (Forward and Reverse) were used in the sequencing reaction (instead of the 
PCR primers) for the M13-tailed primers. For amplicons without M13-tailed primers, the 
initial PCR primers were used. 
 
3.6.2. Sequencing PCR purification 
After cycle sequencing, the samples were purified by Performa® DTR Ultra 96-
Well Plates (Edge Bio, Gaithersburg, MA, USA). The samples were transfered into the 
Performa® well plates, that were centrifuged at 850 rcf in an Eppendorf 5804 R Plate 
Centrifuge (Eppendorf, Hamburg, Germany). These columns have a hydrated gel 
matrix that purified the samples of dye terminators, dNTPs, primers, and buffer. 
 
3.6.3. Sequencing analysis 
The fragments were separated by size through capillarity electrophoresis in 3130xl 
ABI Genetic Analyser (Life Technologies, Foster City, CA, USA) and sequence 
analysis was performed using SeqScape® v2.5 software (Life Technologies, Foster 
City, CA, USA). Identified sequence variants were confirmed in a secondary 
confirmatory PCR of the affected amplicon, in the patient and parents (if available). 
 
 
3.7. Multiplex ligation probe amplification 
The multiplex ligation-dependent probe amplification (MLPA) is a semi-quantitative 
technique that uses a primer pair to amplify several target DNA locations, by using 
probes. This technique allows the detection of gross deletions and duplications in the 
target DNA sequence. Each of the probes is composed of two oligonucleotides that 
target adjacent sites. One of them has a tail sequence complementary to the forward 
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primer, and the other to the reverse primer. Only when both oligonucleotides are 
hybridized with their respective target sequence, they can be ligated into a complete 
probe. Each of the complete probes has a unique size, which can be identified by 
capillarity electrophoresis. By using reference samples it is possible to compare the 
relative quantity of each of the fragments. 
The MLPA analysis was performed using commercial kits P141 and P142 (MRC-
Holland, Amsterdam, the Netherlands), that contain probes for all NIPBL exons. First, a 
mixture was prepared with the DNA samples and the NIPBL probes, and subsequently 
heated to denature followed by overnight hybridization. After this period a DNA ligase is 
added to the mixture to uphold probes’ ligation. These ligation products are finally 
amplified by PCR. Final MLPA products were separated by capillary electrophoresis, 
using a 3130xl ABI Genetic Analyser (Life Technologies, Foster City, CA, USA). 
Results were analyzed using GeneMarker® software (SoftGenetics LLC, State College, 
PA, USA). The population normalization method was used and data was plotted using 
probe ratio. 
 
3.8. High Resolution Melting Curve Analysis 
The hrMCA is a technique used to detect sequence variants in double stranded 
DNA samples. During gDNA amplification by PCR, an intercalating fluorescent dye is 
added at a saturating concentration, and its incorporation and binding to double 
stranded DNA causes it to become florescent. The changes in fluorescence are 
detected by an optical system during real-time. After the PCR step, the specific hrMCA 
thermocycling profile is initiated, samples are heated from between two temperature 
(such as from 50 to 95ºC) in a precise and uniform way. When the specific melting 
temperature of the amplicon is reached, the two DNA strands separate (melt) from 
each other, releasing the intercalated dye which loses its fluorescence. Since the 
melting temperature of an amplicon depends on its DNA composition, a single base 
pair change in the sequence will shift the temperature at which the melting occurs.  By 
comparing melting curve profiles of wild type controls and from patients it is possible to 
identify sequence variants. This technique was used to detect variants in SMC1A gene, 
and for population screening in some NIPBL variants. 
The PCR and subsequently hrMCA were prepared with the following reagents: 
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10 μl of PCR Master Mix 2x (Promega Cat No # M7505) 
6 μl dH2O (nuclease free) 
1 μl EvagreenTM (Biotium, Hayward, CA, USA) 
1 μl Forward Primer + 1 μl Reverse Primer (primers at 5 pmol/μl) 
1 μl gDNA (50 ng/l) 
The samples were placed in a Rotorgene 6000 (Corbett Life Science, Sydney, 
Australia) where the hrMCA program was performed (Table 3.3). The run data were 
analyzed in the Rotorgene 6000 software, and any variation from normal curve pattern 
was sequenced and analyzed (using the same procedures described in 3.6.2. and 
3.6.3. but to SMC1A gene). 
 
 
Table 3.3 :  High Resolut ion Melt ing Curve Analysis for SMC1A  gene 
 Step Temperature (ºC) Time 
Number of 
cycles 
PCR 
phase 
Initial 
denaturing 94 2 min 1 
denaturing 
annealing 
expansion 
94 
56 
72 
20 sec 
30 sec 
30 sec 
35 
 
Final 
extension 
72 5 min 1 
Melting 
phase 
preparation 50 5 min 
 
melting 50 → 95 * - 
* on melting phase, temperatures rise gradually, in steps of +0.05ºC 
followed by a 2 second hold to stabilize and register the fluorescence level 
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3.9. Bioinformatics and databases 
The variations discovered through the different techniques, were analyzed with the 
aid of Alamut 3.0 (Interactive Biosoftware, Rouen, France) mutation interpretation 
software, and the locus specific mutation databases (LSDB) for NIPBL and SMC1A 
genes (http://www.lovd.nl/CDLS). These databases use the Leiden Open Variation 
database (LOVD) software platform, enabling a Web-based listing and curation of 
sequence variations associated with phenotypical information.  
 
3.9.1. Missense mutations analysis 
The bioinformatic analysis of the pathogenicity was made with the help of the 
commercial software Alamut version 3.0 (Interactive Biosoftware, Rouen, France), and 
three other tools: 
  PolyPhen version 2. This software gives a score to the impact of 
substitutions on the structure and function of protein, with a range of 
values from: 0 to 1.000, with the higher value more likely to be 
pathogenic (Adzhubei et al., 2010). 
 SIFT is a sequence homology-based tool that predicts whether an 
amino acid substitution in a protein will have a phenotypic effect. The 
score ranges from 0 to 1. The substitution is predicted damaging is the 
score is <= 0.05, and tolerated if the score is > 0.05 (Pauline and 
Henikoff, 2003). 
 Grantham's distance compares wild type with mutated aminoacids, by 
using physical and chemical parameters (volume, weight, polarity, and 
carbon-composition). The score range from 0 to 215, with higher value 
indicates larger difference. 
 
3.9.2. Algorithms for evaluating splicing 
The splicing mutations found were analyzed through five different methods, 
integrated in the Alamut 3.0 (Interactive Biosoftware, Rouen, France) Splicing 
Prediction Module: 
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 SpliceSiteFinder-like method is based on position weight matrices 
computed from a set of human constitutive exon/intron junctions for donor 
and acceptor sites. 
 MaxEntScan method uses the Maximum Entropy principle (Yeo et al., 
2004). 
 NNSPLICE is a method based on neural networks (Reese et al., 1997). 
 GeneSplicer uses several techniques to detect splice sites, among which 
the Markov models (Pertea et al., 2001).  
 Human Splicing Finder method is based on position weight matrices 
with position-dependent logic (Desmet et al., 2009). 
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4. Results 
 
4.1.  NIPBL gene sequencing 
Mutations in NIPBL gene were screened by direct sequencing which encompassed 
all coding exons and flanking intronic sequences, the methodology is outlined (figure 
4.1) 
 
 
Figure 4.1:  Screening for NIPBL  gene mutat ions by sequencing.  
 
A total of 11 NIPBL point mutations were detected using this approach (Table 4.1). 
These variants seem to be dispersed along NIPBL gene (Figure 4.2) without a clear 
mutational hotspot. 
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a) Mutations are described using NIPBL cDNA reference sequence with accession number: NM_133433.3, according with HGVS nomenclature guidelines; SEQ – Sequencing; MLPA – Multiplex ligation 
probe amplification; b) CdLS clinical classification according to Kline et al., (2007); c) first report describing variant; d) somatic mosaicism suspected; e) other complete deletions of NIPBL has been 
described in the literature, since the breakpoints of this mutation are still unidentified, it is not possible to known if it is the same mutation or not. 
 
Patient Mutationa) Gene Location 
Predicted 
polypeptide change 
Type 
Variant/ 
Origin 
Detection 
Clinical 
Phenotypeb) 
Referencesc) 
P46 c.64+1G>A Exon 2 p.(?) splicing de novo SEQ. mild Borck et al., 2004 
P53 c.86del Exon 3 p.Pro29Hisfs*18 frameshift unknown SEQ. severe Novel 
P31 c.1885C>Td) Exon 10 p.(Arg629*) nonsense  unknown SEQ moderate 
Myake et al., 2005 
P49 c.3316C>T Exon 12 p.(Arg1106*) nonsense de novo SEQ mild Miyake et al., 2005 
P39 c.4422G>T Exon 21 p.(Arg1474Ser) missense de novo SEQ mild Oliveira et al., 2010 
P34 c.5471C>T Exon 29 p.(Ser1824Leu) missense unknown SEQ mild Oliveira et al., 2010 
P14 c.6653_6655delATA Exon 39 p.(Asn2218del) in-frame deletion de novo SEQ moderate Borck et al.,2004 
P20 c.6763+5G>T Intron 39 p.(?) splicing unknown SEQ mild Krantz et al., 2004 
P11 c.6983C>G Exon 41 p.(Thr2328Arg) missense unknown SEQ n.a. Novel 
P09 c.7168G>A Exon 42 p.(Ala2390Thr) missense de novo SEQ moderate Gillis  et al.,2004 
P47 c.7307C>T Exon 43 p.(Ala2436Val) missense de novo SEQ n.a. Novel 
P40 c.(?_-481)_(*927_?)del Exon 1 to 47 
p.(?) large deletion de novo MLPA severe unknowne 
P32 
c.(5710-?)_(*927_?)del Exon 31 to 47 p.(?) large deletion unknown MLPA severe Novel 
Table 4.1: Mutat ions found in NIPBL  gene 
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5’ 3
’ exons 
Patient 
Figure 4.2 :  Distribut ion of NIPBL  mutat ions ident i f ied in this work . The blue l ines represent the int ronic areas of the  gene, and the blue rectangles represent 
exons. The introns are not up to scale, being much larger than represented. Numbers under the exons indicate the exon number.  Green marks above the exons 
represent the locat ion of the point mutat ions reported in this work, and the numbers above indicate pat ient number. Large del et ions found by MLPA are indicated 
as red bars .  
13 
P40 
(deletion of exons 31 to 47) 
(deletion of exons 1 to 47) 
P46  P53 P31 P49 P39 P34 P14 P20 P11  P09 P47 
P32 
FCUP 
Further contributions towards the molecular analysis of NIPBL and SMC1A genes in a cohort of 
patients with Cornelia de Lange Syndrome 
27 
 
 
4.1.1. Mutations causing premature stop codons  
 
Frame-shift mutation - A novel mutation was identified in patient P53, c.86delC 
(p.Pro29Hisfs*18), a single base deletion causing frame-shifting, and creating a stop 
codon located 18 codons downstream (figure 4.3). 
 
 
 
 
 
 
 
 
Figure 4.3:  Sequencing electropherogram of a novel  small 
delet ion causing frame-shif t  located in exon 3 of pat ient P53.  
 
Nonsense mutations – Two nonsense mutations were also detected, c.1885C>T 
(p.Arg629*) in exon 10 (patient P31), and c.3316C>T (p.Arg1106*) in exon 12 (patient 
P20). 
In patient P31 somatic mosaicism was suspected, since the c.1885C>T mutation is 
underrepresented as compared with the wild type allele (figure 4.4A). Due to the lower 
representation of the mutated allele, confirmation was made using a second 
independent technique, namely high-resolution melting curve analysis (hrMCA) (Figure 
4.4B). In addition, this change was not detected in 150 anonymized control samples. 
 
c.86delC 
Reference sequence 
Foward sequence 
Reverse sequence 
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4.1.2. In-frame deletion 
Only one predictably in-frame deletion, c.6653_6655delATA, was found in P14. 
This mutation comprises the deletion of the last two bases of an AAT codon 
(asparagine), and the first base of the following ATT codon (isoleucine). This deletion 
does not cause a shift in the reading frame, resulting in a deletion of a single aminoacid 
(p.Asn2218del). 
 
4.1.3. Missense mutations 
Five mutations predicted to be missense were identified. Three were previously 
reported (in P39, P34, and P09), namely: c.4422G>T (p.Arg1474Ser) in exon 21, 
c.5471C>T (p.Ser1824Leu) in exon 29, and c.7168G>A (p.Ala2390Thr) in exon 42. 
The other two mutations are novel, the mutation in patient P11, c.6983C>G 
(p.Thr2328Arg) a transversion in exon 41 (Figure. 4.5A), and the mutation the 
Figure 4.4:  A) Suspected mosaicism for mutat ion c.1885C>T in exon 10, of NIPBL  of  
pat ient P31,  detected by direct genomic sequencing. B) This mutat ion was conf irmed 
through high resolut ion melt ing curve analysis. The normalized curve is on top right,  and 
dif ference graph on bottom right.  Control samples are shown in blue, and pat ient ’s results  
are in red.  
c.1885C>T 
Reference sequence 
Foward sequence 
Reverse sequence 
A 
B 
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c.7307C>T (p.Ala2436Val), a transition in exon 43 detected in patient P47 (Figure 
4.5B).  
 
 
 
 
 
 
 
 
Figure 4.5 :  Sequencing electropherograms of two missense mutat ions; A) pat ient P11; B)  
pat ient P47 
 
In order to validate the pathogenicity of these variants a population screening was 
performed by hrMCA. Both variants were not detected in at least 150 normal controls. 
Further patogenicity assessment was carried out using different bioinformatic 
algorithms (Table 4.2).  
Both the p.Thr2328Arg and p.Ala2436Val mutations affect highly conserved 
residues (Figure 4.6) located in the Armadillo-type fold protein domain. 
 In addition, the first mutation has a PolyPhen-2 score of 1.000 (probably 
damaging mutation), and a SIFT score of 0.0 (deleterious), with predicted affected 
protein function, and a moderate physicochemical difference between Threonine and 
Arginine (Grantham distance of 71). 
The p.Ala2436Val mutation has a PolyPhen-2 score of 0.977 (probably damaging 
mutation), a SIFT score of 0.0 (deleterious), with a predicted affected protein function, 
and a small physicochemical difference between Alanine and Valine (Grantham 
distance of 64). 
 
c.6983C>G 
(p.Thr2328Arg) 
 
Reference sequence 
Foward sequence 
Reverse sequence 
A B 
c.7307C>T 
(p.Ala2436Val) 
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Table 4.2 :  Evaluat ion of missense variant in terms of pathogenicity
 
a) Score ranging from 0 to 215, with higher value indicates larger difference; b) In the population screening, N/Nt - 
indicates the number of control chromosomes with variant / total number of chromosomes tested.  
 
 
 
Figure 4.6 :  Protein sequence al ignments of delagin from several organisms (orthologs).  
Affected residues,  A) p.Thr2328Arg) and B) p.Ala2436Val  are indicated by boxes.   
Patient Mutation PolyPhen 
v2 Score 
SIFT Score 
Grantham 
distance 
a)
 
Population 
screening 
b)
 
P39 p.(Arg1474Ser) 
0.534 0.0 (deleterious) 110 - 
P34 p.(Ser1824Leu) 
0.987 0.0 (deleterious) 145 - 
P11 p.(Thr2328Arg) 0.998 0.0 (deleterious) 71 0/300 
P09 p.(Ala2390Thr) 0.981 0.0 (deleterious) 58 - 
P47 p.(Ala2436Val) 0.954 0.0 (deleterious) 64 0/300 
A 
B 
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The bioinformatic analysis results support the pathogenicity of the three previously 
described mutations, and suggests that the two novel mutations are also pathogenic. 
 
4.1.4. Splicing mutations 
Two splicing mutations were identified: c.64+1G>A (P46), located in the canonical 
sequence of the donor splice site of intron 2, and c.6763+5G>T (P20), a substitution on 
intron 39 predicted to affect the donor splice site located upstream. Since no RNA 
samples were available from patients, the impact of mutations at the expression level 
was carried out by bioinformatic analysis using several algorithms that evaluate splicing 
(Figures. 4.7 and 4.8). 
 
Figure 4.7:  Evaluat ion of P46 spl ic ing mutat ion c.64+1G>A using Alamut 3.0 ( Interact iv e 
Biosoftware, Rouen, France). On the top is displayed the reference sequence and on the bottom 
the mutated sequence. The column on the left  shows f ive dist inct spl ice site predict ion methods 
(described in 3.9.2) and the grayed numbers to i ts r ight are the  respect ive value ranges for each 
method score. Exons are shown in blue background. Score values are displayed as blue bars for 5 ’  
donor sites, and green for 3’ acceptor si tes. Only scores that dif fer between the reference and 
mutated sequence are highl ighted in the f igure. The high bioinformatic predict ion scores for the 5’  
donor site vanish completely from the mutated sequence, indicat ing a probable loss of the donor 
site with the mutat ion.  
c.64+1G>A 
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Figure 4.8: Evaluat ion of  pat ient P20 spl ic ing mutat ion, c.6763+5G>T using Alamut 3.0 
(Interact ive Biosoftware, Rouen, France) . On the top is  displayed the reference sequence and on 
the bottom the mutated sequence. The column on the left  shows f ive dist inct spl ice site predict ion 
methods (described in 3.9.2) and the grayed numbers to i ts r ight are the respect ive value ranges 
for each method score. Exons are shown in blue boxes. Score values are displayed as blue bars 
for 5’ donor sites, and green for 3’ acceptor si tes. Only scores that dif fer between th e reference 
and mutated sequence are highl ighted in the f igure. Most of the high bioinformatic predict ion 
scores for the 5’ donor site disappear completely from the mutated sequence, indicat ing a probable 
loss of the donor site with the mutat ion . 
 
4.1.5. Variant with unknown significance 
A novel synonymous substitution found in exon 10, c.2727T>C (p.Gly909Gly) 
(Figure 4.9A) was identified in patient P44. Population screening was carried out by 
hrMCA, in 150 anonymized control samples in order to determine its frequency within 
our population, but no mach was found (Figure 4.9B). Patient RNA was extracted and 
converted to cDNA (3.2). The cDNA was amplified by PCR and sequenced (Figure 
4.10). No alterations were found that suggested a splicing defect, moreover 
sequencing results show a 1:1 ratio between normal and mutated allele compatible 
with biallelic expression. 
c.6763+5G>T 
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4.2.  Large mutations detected in NIPBL gene 
This screening was performed in all patients that were negative in the NIPBL gene 
screening for point mutations and small deletions/insertions as previously (see 4.1) 
 
Figure 4.11:  Screening of NIPBL  mutat ions by MLPA.  
c.2727T>C 
Figure 4.9:  Variat ion detected in pat ient P44. A) Electropherogram of synonymous subst i tut ion 
c.2727T>C on exon 10 B) Populat ion screening for c.2727T>C variant,  through High Resolut ion 
Melt ing,  results are displayed on normalized curve (B) and dif ference graph (C). Control samples 
are in blue, and the pat ient samples in  red. 
Figure 4.10 :  cDNA electropherogram of P44 synonymous subst i tut ion on exon 10. Forward 
sequence on the left ,  and reverse sequence on the right.   
 
Reference sequence 
Foward sequence 
Reverse sequence 
A 
B
 
C 
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Results were analysed on GeneMarker® software using a statistical linear 
regression model. Two novel gross rearrangements were found,                           
c.(5710-?)_(*927_?)del, a deletion spanning exons 31 to 47 detected in patient P32 
(Figure 4.12 A and B), and c.(?_-481)_(*927_?)del, a deletion covering the entire 
NIPBL gene (Figure 4.12 C and D) detected in patient P40. 
 
 
Figure 4.12 :  MLPA results of pat ient P32 (A and B, delet ion of exons 31 to 47) and pat ient P40 
(C and D, delet ion of al l  NIPBL exons). The 99% confidence level of the regression is shown within 
the green l ines. Probes with lower rat ios (deleted) are shown as red squares outside the green 
l ines. The green squares represent the normal DNA copy numbers and the blue squares the cont rol 
probes. Standard deviat ion is shown in top left  corner of  each plot.  A and C) MLPA probe set P141 
(odd number exons).  B) and D) MLPA probe set P142 (even number exons).  
 
4.3.  Mutation screening for SMC1A gene 
 
This screening was made in patients previously tested with negative results for 
mutations in the NIPBL gene. Since only a low percentage CdLS patients have been 
reported with mutations in this gene (~5%), and because this gene has a limited 
number of polymorphism and small exons (most exons are between 100 and 250 bp, 
which allowed the design of small amplicons feasible for hrMCA technique), a different 
approach, faster and cost-effective was used to screen SMC1A for mutations. 
A B 
C D 
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Figure 4.13: Strategy for SMC1A mutation screening by hrMCA following confirmation by sequencing. 
 
An initial screening by high resolution melting curve analysis was done. In each run 
three replicates for each sample and at least four negative controls were, in order to 
minimize the possibility of inconsistent results which could result in false 
positive/negative. After this screening, any sample that presented a shift/change on the 
melting profile was sequenced to test for variants.  
Three cases (not included in this study) presented differences from the normal 
melting curve in several amplicons, but after being sequenced presented no variance in 
the DNA sequence. After close analysis, it was detected that their melting curve 
divergence was similar to samples extracted from blood with Lithium Heparin 
anticoagulant addictive. Since samples in extracted with this addictive could not be 
compared in with the control samples extracted from blood with K3-EDTA 
anticoagulant addictive, they were removed from this study.  
 
 
Figure 4.14 :  Normalized High Resolut ion Melt ing Curves, for amplicons of exons 1 to 6a (exon 
6 had to be ampli f ied in two amplicons due to i ts larger size).  In Y axis is represented the relat ive 
f luorescence of the samples (from 0 to 100), and on X axis temperature . 
exon 1 
exon 4 
exon 3 
exon 5 exon 6a 
exon 2 
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Figure 4.15 :  Normalized hrMCA prof i les  for amplicons of exons 6 to 25. In Y axis is represented 
the relat ive f luorescence of the samples (from 0 to 100), and on X axis the sample temperature.  
exon 9 exon 11 
exon 12 
exon 22 exon 23 
exon 24 exon 25 
exon 6 (b) exon 8 exon 7 
exon 13 exon 14 
exon 15 exon 16 exon 17 
exon 18 exon 19 exon 20 
exon 21 
exon 10 
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The melting curves obtained for each amplicon are shown below (figure 4.14 and 
4.15). To validate this technique for diagnosis, samples that turned out negative for 
variations in each of the amplicons were previously sequenced, to discard false 
negatives. This sequencing is still ongoing, but at least five different samples for each 
amplicon were sequenced, and no false negative result has appeared so far.   
Using hrMCA as a screening method one variation was found in exon 9 of SMC1A 
of patient P17 (Figures 4.15 and 4.16). Upon DNA sequencing this shift on the melting 
profile was confirmed as being a true sequence variant: c.1487G>A, a previously 
reported missense mutation (p.Arg496His), first reported by Deardorff et al., (2007) 
(Figure 4.16).  
 
 
 
 
 
  
Figure 4.16:  SMC1A missense mutat ion, detected through High 
Resolut ion Melt ing (A), (normalized curve on top, and dif ference graph at  
bottom). Control samples are in blue,  and the pat ient samples in red. (B) 
Sequencing electropherogram of pat ient sample conf irming the presence 
of a sequence variant (mutat ion c.1487G>A).  
 
 
c.1487G>A  
 
B 
A 
Reference sequence 
Foward sequence 
Reverse sequence 
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5. Discussion  
 
5.1.  Mutations identified in NIPBL 
As shown in the results section this study includes the molecular characterization 
of thirteen patients with NIPBL mutations. Eleven cases had sufficient clinical data 
allowing their clinical classification: 3 (27%) were severe, 3 (27%) moderate and 5 
(46%) have a milder CdLS phenotype. Considering the entire Portuguese CdLS cohort 
(additional thirteen CdLS cases reported by our group in 2010) only five patients in a 
total of 26 were classified as severe. This numbers contrast with the overall 
percentages reported in the literature, where 40% of the CdLS cases were classified as 
severe (Oliveira et al., 2010). Perhaps, this may be partially explained by the high 
coverage of routine ultrasound scans during pregnancy in Portugal. The use of this 
non-invasive prenatal screening technique has been proven very successful to prevent 
several developmental defects, including upper limb reductions commonly associated 
with the severest forms of CdLS. It is conceivable that these cases are identified by 
prenatal scans resulting in medical termination of pregnancies, which in turn 
contributes to lower the prevalence of the severe form of the disease. 
In this work three novel mutations predicted to have the most drastic effects on the 
protein were identified in patients with a severe phenotype. In the first case a complete 
deletion of NIPBL gene was identified in patient P40. The second patient with a severe 
phenotype (P2) has a large deletion that encompasses a significant part of NIPBL 
(from exons 31 to 47); if efficient translation occurs this may lead to an aberrant 
polypeptide with loss of part of the armadillo domain. The third patient (P53) has a 
small frame-shift deletion (c.86del) that prematurely truncates the protein, where the 
predicted ORF reading frame is limited to 47 codons. In this subset of our CdLS cohort, 
the nonsense mutation (p.Arg1106*) identified in patient P49 was the only apparent 
exception to this genotype-phenotype correlation. This mutation should be further 
analyzed at the mRNA level, to exclude possible effects on splicing, such as exon 
skipping or activation of a cryptic splice site. Some of these splicing defects lead to an 
in-frame deletion at the protein level thereby explaining the milder form of CdLS. 
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Figure 5.1 :  Representat ion of the NIPBL gene with the distribut ion of al l  known point and small  del/ ins mutat ions throughout the gene. The 
blue rectangles represent the exons,  and the white rectangles represent the int rons, and the blue rectangles The i ntronic region is are not up to 
scale, being much larger than represented especial ly intron one. The pale blue rectangles are the non-coding exonic areas of the gene. Numbers 
under the exons indicate the odd exons. Each red bar marked above represents the mutat ion frequency along the gene.  
5’ 3’ 
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The eleven point mutations detected in the NIPBL seem to be spread along the 
gene without an apparent mutational hotspot, although their distribution seems non-
random. The majority of the reported NIPBL mutations are located in regions of the 
gene with a higher mutation frequency (Figure 5.1) (Oliveira et al., 2010). A probable 
explanation to this is the presence of gene specific sequence context such as 
hypermutable CpG dinucleotides that might be affected by methylation-mediated 
deamination (Cooper and Youssoufian, 1988), regions of repetitive sequences (like 
short tandem repeats) and/or homopolymeric nucleotide stretches that are susceptible 
to replication errors. In fact, the mutation detected on patient P14 
(c.6653_6655delATA) is one of the most frequent recurrent mutations of the NIPBL 
gene, being also an example of a mutation occurring in a repetitive sequences stretch 
(deletion of one of three ATA repeats). In addition, five single substitutions c.64+1G>A 
(patient P46), c.1885C>T (patient P10), c.3316C>T (patient P49), c.5471C>T (patient 
P34), c.7168G>A (patient P09) are located in CpG dinucleotides. Seven mutations 
including five missense mutations, an in-frame deletion and a change affecting splicing 
were found inside the armadillo domain of delangin. This protein domain occupies a 
considerable part of the gene (exons 13 to 37) and it is located in a highly conserved 
region (Jahnke et al., 2008).  
 
5.1.1. Detection of large NIPBL deletions by MLPA 
Two large deletions in the NIPBL gene were found in our patients:  
c.(?_-481)_(*927_?)del and c.(5710-?)_(*927_?)del. Although, CdLS diagnosis has 
been confirmed, further molecular characterization should be made to determine the 
breakpoints of these mutations. In the case of the patient with a complete deletion of 
NIPBL (P40), this delineation would be of clinical importance to confirm or exclude the 
involvement of neighboring genes. However, the patient has decease and there are no 
additional biological samples available for analysis. The detection of two NIPBL gross 
deletions in 3.8% of our patients (2/53) is quite relevant as compare to other CdLS 
genes detection rates (please see section 5.3). It shows the importance of using MLPA 
technique after exclusion of point mutations by genomic sequencing in order to 
increase the overall NIPBL mutation detection rate. These numbers are very similar to 
those reported in a recent study, where the same strategy detected mutations in 3.5% 
of patients (7/200) (Russo et al., 2012). Overall, these results confirm the 
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recommendation for the use of MLPA technique on NIPBL in a routine molecular 
diagnostic setting. 
 
5.1.2. Somatic mosaicism 
As it was shown in the results section, the c.1885C>T mutation (p.Arg629*) in exon 
10 of patient P31 was suspected of somatic mosaicism. Compared to the wild type (wt) 
the mutated allele is under-represented, <25% of the fluorescence intensity of the wt 
allele, estimated by comparing both signals in the sequence electropherogram. This 
mutation if not carefully looked-up could have been missed during analysis using 
default settings. Myake et al. (2005) reported a Japanese patient having this nonsense 
mutation associated to a severe phenotype; while patient P31 was classified as 
moderate. This discrepancy is also in favor of mosaicism, since patients with mosaic 
mutations tend to express an attenuated phenotype than non-mosaic patients with the 
same mutation (Kluwe et al., 2003). For further characterization of this case 
quantitative methods such as real-time PCR should be applied to quantify the 
percentage of cells with the mutation as compared to wt, ideally this quantification 
should be perform on DNA obtained from different tissues (from distinct germ layers). 
Mendelian disorders with a high frequency of de novo mutations (as is the case of 
CdLS) have a relatively frequent occurrence of somatic mosaicism (Castronovo et al., 
2010). However very few of such cases have been reported in NIPBL so far 
(http://www.lovd.nl/NIPBL, last accessed September 2012). It is possible that some 
somatic mutations with low-level mutant alleles could escape detection by routine 
sequencing methods. Somatic mosaicism in NIPBL gene could help to explain the 
phenotypic variability of patients, and is another source of clinical and genetic 
heterogeneity of this syndrome (Castronovo et al., 2010). These observations raise the 
possibility that mutation rates of genes involved in CdLS are currently underestimated. 
In addition, as demonstrated by the use of hrMCA technique it is important to combine 
different techniques for diagnosis purposes. In molecularly unresolved cases next 
generation sequencing (NGS) would be a powerful tool to detect pathogenic mosaic 
mutations since this approach, specially using a high coverage strategy, is sensible 
enough to detect low allele frequencies (Pagnamenta et al., 2012). Furthermore, Next 
generation sequencing (NGS) allows the screening of several genes simultaneously 
which is another advantage for its use in this field. 
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5.1.3. Novel silent polymorphism 
The apparently silent substitution c.2727T>C sequence variant in NIPBL detected 
in patient P44 was further studied at the mRNA level. We have shown that this change, 
although it was not detected in control samples, does not have an impact on splicing 
(inclusion of exon 10). Very recently this variant was reported in the Single Nucleotide 
Polymorphism database of NCBI (dbSNP, rs148394805), as a rare variant with an 
allelic frequency of only 0.2%. Due to its very low frequency it was not detected during 
our population screening. 
 
5.2. Implementation of hrMCA for SMC1A 
One of the goals of this work was to set up a molecular diagnostic for mutation 
screening in SMC1A gene. The fast, efficiency and low-cost of the hrMCA technique, 
combined with the gene characteristics (small easily amplifiable exons and limited 
number of polymorphisms) made this technique an ideal choice for the mutation 
screening of SMC1A. This is the first known study to apply hrMCA technique for 
mutation screening on SMC1A gene. While there are no references in the literature for 
the use of the technique in this gene, studies in other genes stated the robustness, 
high-throughput, high sensitivity and low false positive ratio of this technique (Millat et 
al., 2009; Santos et al., 2012). Because of its high sensitivity the melting curve profile 
can be altered by several secondary factors like the presence of primer-dimers, 
amplification of non specific products, or using DNA templates with different 
concentrations or quality/purity. These might cause false positives results but it can be 
easily avoided by a good PCR optimization. The use of at least three replicas for each 
sample and the inclusion of previously genotyped controls may avoid problems with 
individual samples. Amplicons that present a shifted melting curve have to be 
sequenced. Although, this technique is extremely sensitive to detect a variation, it 
cannot determine what the precise sequence change is unless positive controls are 
added to the same run. DNA sequencing after hrMCA is also useful to exclude false 
positives. hrMCA scanning accuracy depends on high quality PCR (Santos et al., 2012), 
but as long as optimal PCR conditions can be assured, and if combined with genome 
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sequencing to validate results, this technique can provide an fast and effective way of 
screening SMC1A gene for mutations. 
The proof-of-principle of the successful deployment of this technique for mutation 
scanning in SMC1A was the identification of a sequence variant (c.1487G>A) in patient 
P17, initially detected by hrMCA and later confirmed by genomic sequencing. This 
missense mutation (p.Arg496His) identified in exon 9 of SMC1A, was previously 
reported in six other CdLS patients (Deardorff et al., 2007). The mutation occurs in the 
SMC flexible hinge domain. A previous study reported that mutations in this domain 
increase the affinity for DNA binding, comparing with the wild type proteins (Revenkova 
et al., 2009). 
 
5.3.  Mutation detection rate 
The Portuguese CdLS patient cohort studied by our group includes a total of fifty-
three individuals studied by different techniques applied to SMC1A and NIPBL genes. 
Overall results have allowed the successful molecular characterization of twenty-seven 
patients, the majority with mutations in NIPBL gene and only one case with a 
pathogenic variant in SMC1A (Table 5.1). 
The mutation detection rate for NIPBL gene is 49.1% (26/53) which is within the 
range of values (40-60%) indicated in the literature for this locus (Russo et al., 2012). 
Although some research groups report mutation detection rates for NIPBL gene up to 
60%. This might be attributed to different inclusion or exclusion criteria for selection of 
patients that could lead for the mildest phenotypes to be excluded from NIPBL gene 
analysis.  
Concerning SMC1A gene, the mutation detection rate was 1.9% below the 5% 
detection rate reported in the literature by other groups (Russo et al., 2012). One 
possible explanation may be attributed to the fact that SMC1A gene was not completed 
sequenced in all NIPBL-negative cases. It is conceivable that some mutations may 
have not been detected by hrMCA that was used as a prospective scanning method. 
SMC1A sequencing analysis should be performed in all molecularly unresolved cases 
to exclude the involvement of this locus. 
 
FCUP 
Further contributions towards the molecular analysis of NIPBL and SMC1A genes in a cohort of 
patients with Cornelia de Lange Syndrome 
44 
 
 
 
 
Table 5.1 :  Overal l  results of the genetic analysis of NIPBL  and SMC1A  genes in the Portuguese 
CdLS pat ient cohort.  
 
SEQ- genomic sequencing; MLPA- multiplex ligation probe amplification; HRM- high 
resolution melting; P- patients; * patients described in a previous publication (Oliveira et al., 
2010). 
 
5.4.  Bioinformatic tools and databases 
Nowadays, bioinformatics tools are essential resources in a clinical molecular 
genetics laboratory. From primer design, to sequence analysis and mutation 
interpretation these applications speed up work and provide useful additional data for 
mutation validation. During this work several in-silico tools were used to validate new 
missense changes and mutations that affected splicing. Unfortunately, in some of the 
patients it was not possible to obtain new biological samples essential to perform 
additional studies, so the use of bioinformatic prediction tools can help to ameliorate 
these limitations. 
The continuous build up of new sequence variant led the international scientific 
community to create breakthrough initiatives such as the Human Variome Project 
(HVP) (Kohonen-Corish et al., 2010). One of the main objectives of HVP is the creation 
of LSDBs for all Human genes implicated in mendelian diseases. The development and 
update of such databases are greatly dependent on the activities of several research 
groups. The use of mutation databases like the LSDBs for NIPBL and SMC1A, are an 
efficient way of sharing information regarding variants and phenotypes. Since obtaining 
evidence of pathogenicity of variants is costly and time-consuming these databases are 
 Patients 
Mutation positive CdLS cases 
 
Negative 
cases NIPBL 
(SEQ) 
NIPBL 
(MLPA) 
SMC1A 
(HRM) 
Total 
Phase 1 
(P1-39) 
39 
20 
1 1 22 17 
(7+13*) 
Phase 2 
(P40-53) 
14 4 1 0 5 9 
Total 53 
24 
(11+13*) 
2 1 27 26 
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also important resources for diagnostic laboratories, which can rapidly cross-check if a 
sequence changes in one of the CdLS genes have been already reported. 
 
5.5.  Procedure for the molecular diagnostic of CdLS patients 
Due to the genetic complexity of CdLS which concerns different mutation types and 
multiple genes, a procedure flowchart for the genetic molecular diagnostic of CdLS is 
proposed (Figure 5.2). The sequential order of the different techniques was established 
considering their sensitivity to optimize time and economical resources. The first gene 
that should be considered for analysis is NIPBL since the majority of mutations 
described up to now are related to this locus. Direct genomic sequence should be the 
first technique to be applied, considering that the most frequent variants are point 
mutations or small deletions/insertions. Although it was not included in the flowchart, it 
is of importance to emphasize that approximately 80% of NIPBL mutations described to 
date are located on 21 exons (out of a total of 47) (Oliveira et al., 2010). Therefore, 
NIPBL sequencing step may be sub-divided in two steps, starting by exons with higher 
mutation frequency and afterwards sequencing the remaining 26 exons of NIPBL with 
less mutations reported. Theoretically, this partial NIPBL gene sequencing would allow 
detection of mutations in about one third of the CdLS patients. After NIPBL genomic 
sequencing, cases still unresolved should be submitted to MLPA technique to detected 
large deletions or duplication involving one or more exons of NIPBL. As discussed 
above, this technique has a greater mutation detection rate than sequencing SMC1A 
itself. Results have shown that hrMCA enables a fast and cost-effective scanning of 
SMC1A. However, hrMCA technique must always be validated by genomic sequencing 
to exclude false positives and polymorphisms. 
As mentioned in the Introduction, besides NIPBL and SMC1A other genes, to be 
precise SMC3, RAD21, and HDAC8, have been associated with milder CdLS (or 
Cornelia-like) phenotypes in a limited number of cases (Revenkova et al., 2009; 
Deardorff et al., 2012a). In spite of the low mutation detection rate, these genes should 
be considered for genetic analysis, especially if there is a specific clinical request 
based upon characteristic phenotypic traits or suggestive patterns of inheritance (such 
as X-linked). 
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Figure 5.2:  Flowchart for a proposed procedure for the genetic molecular diagnost ic of CdLS  
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5.6.  Future perspectives 
All the available data within public domain suggests that at least 30% of CdLS 
patients are still molecularly unsolved. This prompts to new lines of research dedicated 
to the identification of new genetic causes for CdLS. The obvious candidates can be 
found among the genes involved with the cohesion complex and their regulators. A 
new technological paradigm is currently changing the face of Human Genetics, next 
generation sequencing (NGS), which consist in extremely high-throughput genetic 
analyzers. NGS technology can be used for CdLS research by at least two different 
approaches. The first is based on the development of custom genomic libraries for 
targeted resequencing where a number of candidate genes (such as those involved in 
the cohesin complex) are selected and analyzed simultaneously in several patients. An 
alternative strategy is in well selected CdLS patients perform a whole exome 
sequencing, meaning that all the coding regions of all known Human genes are 
sequenced to identify variants responsible for CdLS. 
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Annex I 
 
 
Clinical Features used for Kline et al., 2007 scoring system 
 
a) facial features – including synophrys with arched fine eyebrows, long 
eyelashes, short nose, anteverted nares, long prominent philtrum, thin lips, 
high palate 
b)  delayed growth – small stature, microcephaly 
c) developmental delay – mental retardation, learning disabilities, speech and 
language deficits) 
d) behavioral issues – like attention deficit disorder,  obsessive-compulsive 
disorder characteristics, anxiety, aggression and self-injury, and autistic-like 
features 
e) musculoskeletal anomalies – extremities with reduction defects, arm and hand 
anomalies, and chest, back, and hip complications 
f) neurosensory and skin problems – including ophthalmic, auditory and central 
nervous systems, hirsutism, cutis marmorata 
g)  other major systemic involvement – ex.: gastroesophageal reflux disease, 
genitourinary anomalies, congenital heart disease) 
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Annex II 
 
CdLS genetic study request form 
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Annex III 
 
Table of primers used in this study 
a. NIPBL (Accession Number NM_133433.3) 
  
a.1 M13-Tailed custom primers 
Primer 
Sequence 
(5’ -> 3’) 
Ta 
annealing 
temperature 
g.NIPBL-2-F 
g.NIPBL-2-F 
TGTAAAACGACGGCCAGTAGGTTGAACAAACCAAAGCAGTAAC 
CAGGAAACAGCTATGACCAAGGGCAGTTTCAGTTGCTATTTC 
58 
g.NIPBL-3-F 
g.NIPBL-3-R 
TGTAAAACGACGGCCAGTCCCAAAATACAGATAAGCACTAAAGAGAC 
CAGGAAACAGCTATGACCTTCTGAAATAAAACCAGGAATACGG 
58 
g.NIPBL-4-F  
g.NIPBL-4-R  
TGTAAAACGACGGCCAGTAAATTCATATTGTTGGCCATACC 
CAGGAAACAGCTATGACCCAAGAATCTTATCAGTTTAGTTTCCTTC 
58 
g.NIPBL-5-F  
g.NIPBL-5-F  
TGTAAAACGACGGCCAGTACAGTTTTACAGCGTCTATATTTTGCTC 
CAGGAAACAGCTATGACCAATCCACCATTACCTAAATGTATGAACC 
58 
g.NIPBL-6-F 
g.NIPBL-6-R 
TGTAAAACGACGGCCAGTACGGAGCATGGCTTTAAGTACC 
CAGGAAACAGCTATGACCCTGAATCCAAAAAGCCAAAATG 
58 
g.NIPBL-7-F  
g.NIPBL-7-R 
TGTAAAACGACGGCCAGTTCTGGCAGAGTGTTAAGATTTGATG 
CAGGAAACAGCTATGACCCCTGCTCTAGACTAAGCTCTGTATGTG 
58 
g.NIPBL-8-F 
g.NIPBL-8-R 
TGTAAAACGACGGCCAGTTGCCATGCTTAGGCTGTTG 
CAGGAAACAGCTATGACCAAATCCCATGATCCAGACCTG 
58 
g.NIPBL-9-1-F  
g.NIPBL-9-1-R 
TGTAAAACGACGGCCAGTAGCTAAACAACTGTGTGGGACAAG 
CAGGAAACAGCTATGACCTTCCACACCAGAAATCATATCCTC 
58 
g.NIPBL-9-2-F 
g.NIPBL-9-2-R 
TGTAAAACGACGGCCAGTAGTTCTCCATCCAAGGACTCTACTAAAC  
CAGGAAACAGCTATGACCGCCAATGCATCCAATTCCAC 
58 
g.NIPBL-9-3-F 
g.NIPBL-9-3-R 
TGTAAAACGACGGCCAGTAACAAACAGCATTCCTTCCAGC 
CAGGAAACAGCTATGACCCAGACCTGTAGTAGAGAATTACCAAATCTC 
58 
g.NIPBL-11-F  
g.NIPBL-11-R 
TGTAAAACGACGGCCAGTCTTCATTTTTATGGTGGTGTCATG 
CAGGAAACAGCTATGACCAACACATCAACCTGCTTTTAAACTC 
58 
g.NIPBL-12-F  
g.NIPBL-12-R 
TGTAAAACGACGGCCAGTATCACTGAATTTCCTAGACCCTATGG 
CAGGAAACAGCTATGACCAAGTACTGAAATGCAGGACTGACAAC 
58 
g.NIPBL-13-F 
g.NIPBL-13-R 
TGTAAAACGACGGCCAGTTTCATCAGTGTCAACGGATTTC 
CAGGAAACAGCTATGACCGTCCATCATTTCTGCAAGAGAG 
58 
g.NIPBL-14-F  
g.NIPBL-14-R 
TGTAAAACGACGGCCAGTAGCATATGAACCAAAACTAACACC 
CAGGAAACAGCTATGACCCATAGTTAGGGATTCAGAAAAGAGC 
58 
g.NIPBL-15-F  
g.NIPBL-15-R 
TGTAAAACGACGGCCAGTGCGTCTTAGGTTATTTGTTTAGTTTGC 
CAGGAAACAGCTATGACCGCCTCTTTCAATGCAGTAATATGATTCT 
58 
g.NIPBL-16-F  
g.NIPBL-16-R 
TGTAAAACGACGGCCAGTTCCTCCATAGCTCAAAGGGAATAA 
CAGGAAACAGCTATGACCGGCATGGGAAGAGATTAATGACA 
58 
g.NIPBL-17-F  
g.NIPBL-17-R 
TGTAAAACGACGGCCAGTCACATCATAACACTTTTCCACCAGT 
CAGGAAACAGCTATGACCTTCTGAGATTTTCCCTGACAAGTAGAA 
58 
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g.NIPBL-18-F  
g.NIPBL-18-R 
TGTAAAACGACGGCCAGTGCTTTATCTTCCAGGTTCTGTAGCTAG 
CAGGAAACAGCTATGACCAGTGCTGGTCTTATTATTGAGTGAGC 
58 
g.NIPBL-19-F  
g.NIPBL-19-R 
TGTAAAACGACGGCCAGTGGGAAACAGAGAAAAGAATAGATGCT  
CAGGAAACAGCTATGACCGAATGTACTGAAAACCAGGTATCTTCAT 
58 
g.NIPBL-20-F  
g.NIPBL-20-R 
TGTAAAACGACGGCCAGTGGAAAATAGAGCAGCTTACCTTAGATACTG  
CAGGAAACAGCTATGACCCATGCTGTTCTGATGTAACTGCC 
58 
g.NIPBL-21-F  
g.NIPBL-21-R  
TGTAAAACGACGGCCAGTCACAATAAGCACTAAGATCATGCCTAG 
CAGGAAACAGCTATGACCGGGTGACAGAGCGAGACTCC 
58 
g.NIPBL-22-F  
g.NIPBL-22-R  
TGTAAAACGACGGCCAGTCAATCCATTTCTTTCTGTTCTGACC 
CAGGAAACAGCTATGACCAAGATCAAGAAACCAAGTGTCAGGA 
58 
g.NIPBL-23-F  
g.NIPBL-23-R 
TGTAAAACGACGGCCAGTGGAGAAAGTGGAGTTTGTGAAATAGAC 
CAGGAAACAGCTATGACCAAAGAATTCATCATCTGTGAATCAGAGTAC 
58 
g.NIPBL-24-F  
g.NIPBL-24-R  
TGTAAAACGACGGCCAGTGACTTTATGGGACAATATCACAGGAA 
CAGGAAACAGCTATGACCCCCTGTTAGACTAAATAATTCATTCTCAGG 
58 
g.NIPBL-25-F  
g.NIPBL-25-R 
TGTAAAACGACGGCCAGTCAAAAAAGGCAAACTTCAGCTATCA 
CAGGAAACAGCTATGACCTAAGACAAATCAACCCAAAGCATTC 
58 
g.NIPBL-26-F  
g.NIPBL-26-R 
TGTAAAACGACGGCCAGTCATGATGTTGTCCTTGATTAAGTAGTTG 
CAGGAAACAGCTATGACCCATAGTCCACAGTATCAGAGTTCATCCT 
58 
g.NIPBL-27-F  
g.NIPBL-27-R 
TGTAAAACGACGGCCAGTCACACCTTCTCAGTTTAGCACATTAA 
CAGGAAACAGCTATGACCGCCGGAGAACCTAAAAACAAA 
58 
g.NIPBL-28-F  
g.NIPBL-28-R 
TGTAAAACGACGGCCAGTAACGAAAGGCTCCAAAGTATGG 
CAGGAAACAGCTATGACCGAACACCTCGTTGCATATCAAGC 
58 
g.NIPBL-29-F  
g.NIPBL-29-R 
TGTAAAACGACGGCCAGTCCCAGTATTCTAGCAAGGGTAAAG 
CAGGAAACAGCTATGACCCCCATGTGGTTCCTATCATCTAC 
58 
g.NIPBL-30-F  
g.NIPBL-30-R 
TGTAAAACGACGGCCAGTTCTAGTCTTGTGTCCAGGGCTTAAC 
CAGGAAACAGCTATGACCTATTACCACTGAGGAATTGGTTGG 
58 
g.NIPBL-31-F  
g.NIPBL-31-R 
TGTAAAACGACGGCCAGTCCTGGCAGTTTGTGTTTTGATTAG 
CAGGAAACAGCTATGACCGGCAGCAGTACGAAATGTCAAG 
58 
g.NIPBL-32-F  
g.NIPBL-32-R 
TGTAAAACGACGGCCAGTACGTTGGTAAATGGTTGTGTTACTG 
CAGGAAACAGCTATGACCAAAACCACAACCAGGCAACTG 
58 
g.NIPBL-33-F 
g.NIPBL-33-R 
TGTAAAACGACGGCCAGTTGGAATAGGGAGAAAGGGAAGG 
CAGGAAACAGCTATGACCGCAGAGCCAGAGGCAAAAATG 
58 
g.NIPBL-34-F  
g.NIPBL-34-R 
TGTAAAACGACGGCCAGTCATGGCCTCTTGTTCTTTATCTTG 
CAGGAAACAGCTATGACCAGTTGATCTGTCAGTGAGAATGTGG 
58 
g.NIPBL-35-36-F  
g.NIPBL-35-36-R 
TGTAAAACGACGGCCAGTCAAAATGCCCTATTTCTGCCC 
CAGGAAACAGCTATGACCCACACCTCATAATTTCCTCGAGTCTAG 
58 
g.NIPBL-37-F  
g.NIPBL-37-R 
TGTAAAACGACGGCCAGTGGGTGACAGTGAGACTCCATCTC 
CAGGAAACAGCTATGACCGAGCAGCACTGTTTTCAGAATTTTC 
58 
g.NIPBL-38-F  
g.NIPBL-38-R 
TGTAAAACGACGGCCAGTACAGACTGATACTTTGAATGCCACTG 
CAGGAAACAGCTATGACCCCTACATTCTATACACCAAATCCTACTGC 
58 
 
 
 
a.2 Primers used from Krantz et al., 2004 
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Primer 
Sequence 
(5’ -> 3’) 
Ta 
annealing 
temperature 
g.NIPBL-10A-F  
g.NIPBL-10A-R 
TTGCATTTGCATTTTACTCCA 
GTGTCTCAGGATGGTTTTCTGG 
58 
g.NIPBL-10B-F  
g.NIPBL-10B-R 
TACGGGAAATGGGTCAAGGC 
AGGCTCAACTATGGTGCTCTCG 
55 
g.NIPBL-10C-F  
g.NIPBL-10C-R 
TGAGAGCAGAACAACTGAATGC 
TGGCTTTCCAGGAATCCCTCC 
55 
g.NIPBL-10D-F  
g.NIPBL-10D-R 
AGGTGAGAGCCGCCCTGAAACTC 
CACGAGGACTGTCAGGTCTTGA 
55 
g.NIPBL-10E-F  
g.NIPBL-10E-R 
TGAATCAGGGGACTCAAGGG 
AGGGAACTTCTTGATTTGTCCTC 
55 
g.NIPBL-10F-F  
g.NIPBL-10F-R 
AGGAGCTAAGCCTGTAGTTGTG 
CTTGAGTAGTGGGTGGGGAAGA 
55 
g.NIPBL-39-F  
g.NIPBL-39-R 
CTCTAGGTAAGGCCACCAGCAT 
TAGACCTCAGCATAAGGACTGC 
55 
g.NIPBL-40-F  
g.NIPBL-40-R 
CAGATTAAGAACCATTGAGCC 
GCAGTAATCATAACCCAAGAG 
58 
g.NIPBL-41-F  
g.NIPBL-41-R 
AGTGTGAGAATGCTTTATGTT 
ATTATGAATGTGGGCAGAGCA 
55 
g.NIPBL-42-F  
g.NIPBL-42-R 
ATGAAGCTAGCCTCAGAATGT 
CAAAATTTCCCCTTCACTTCTGA 
58 
g.NIPBL-43-F  
g.NIPBL-43-R 
GTGAGGTGAAAGTGCCCTGTA 
TCCCAAGTCAAGTATTGCCCAG 
52 
g.NIPBL-44-F  
g.NIPBL-44-R 
CAAGCTGTTGAATGGAGCATAC 
CATGAGCCACCACACCCAGC 
58 
g.NIPBL-45-F  
g.NIPBL-45-R 
TCCAAATACGTTGTTTCCATAG 
TCAATGTGAAGGAGATAGTTAT 
58 
g.NIPBL-46-F  
g.NIPBL-46-R 
CCACACCAAACTACTGCCATAG 
CATTTTACGTAATACGCTGCG 
58 
g.NIPBL-47A-F  
g.NIPBL-47A-R 
GTCACGGTGCGTCTCATTGC 
TAGTGTCTACCCAAGGCACCA 
58 
g.NIPBL-47B-F  
g.NIPBL-47B-R 
GGCTTCAGTGTTCAGTGGATG 
TTTGCCCAACATTTCCTTC 
58 
g.NIPBL-47C-F  
g.NIPBL-47C-R 
TGAAGAGTAAGTGGAACCTGG 
GCTAAAGAAAGCCATCCGC 
58 
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b. SMC1A (Assession Number NM_006306) 
 
Primer 
Sequence 
(5’ -> 3’) 
Ta 
annealing 
temperature 
g.SMC1A-1F 
g.SMC1A-1R 
GGCCTGTCCTACTGCCGC 
CCGCGACGTTTCAGGTTAC 
58 
g.SMC1A-2F 
g.SMC1A-2R 
GACTTTCCCTCTACTGCCTCGTC  
CCTCCTTCCTGTCCCAATCAA 
58 
g.SMC1A-3F 
g.SMC1A-3R 
TTGGGACAGGAAGGAGGCC 
GGGATGGGACATGGTCTGG 
58 
g.SMC1A-4F 
g.SMC1A-4R 
TGAACTGGGTTGGCTGGG 
TGGTCCCTCAGAGCCAAGAG 
58 
g.SMC1A-5F 
g.SMC1A-5R 
GCCTTATCGATGCACCCC 
GGTTTCCCACAAGTTGCAGG 
58 
g.SMC1A-6F 
g.SMC1A-6R 
GAAAAGCCTGGGAACCCTC 
CCACTGACAGCATCTCCTTCTC 
58 
g.SMC1A-6bF 
g.SMC1A-6bR 
AGAAGCGGCCTCAGTACATCAA 
TCAGCCCAGGGATCTCCTC 
58 
g.SMC1A-7F 
g.SMC1A-7R 
ATCCCTGGGCTGACATCTG 
TCTGTGGACCATCATCCCTAATC 
58 
g.SMC1A-8F 
g.SMC1A-8R 
CCCATGGTCTTGGCGTAAACT 
GGCTGGTGAGAAAATACTCCTGG 
58 
g.SMC1A-9F 
g.SMC1A-9R 
TCTGAGCCAGGAGTATTTTCTCAC 
GTGTAAGTGCTCAGGAAATGAGTTC 
58 
g.SMC1A-10F 
g.SMC1A-10R 
GCTTCATACTTCAGTTTTCCCTTCC 
CCTTGAACACTGGCCTGACC 
58 
g.SMC1A-11F 
g.SMC1A-11R 
TTGTGTTCTGCCACTGACTGAG 
CTGAGCCTGTCCAGCTCCAG 
58 
g.SMC1A-12F 
g.SMC1A-12R 
CCCCTCTTCTCTCTTCCCCC 
GGACTCCCACTGCTAAAAACAGC 
58 
g.SMC1A-13F 
g.SMC1A-13R 
GCCACCACCTTACCACCTAGC 
GCCTTTGGAGAACAGGGCTG 
58 
g.SMC1A-14F 
g.SMC1A-14R 
TCCAAGGAGCCTGGTCTGC 
TGCCCTGACACACACGCTG 
58 
g.SMC1A-15F 
g.SMC1A-15R 
GACAGACTAAAAGGGCCGATG 
TGACCCTTGCCTATGACAGC 
58 
g.SMC1A-16F 
g.SMC1A-16R 
GAGATTATGAGTGATTCTCCCCCC 
GGACATTATCCTTCTGTCTGTCGTATT 
58 
g.SMC1A-17F 
g.SMC1A-17R 
GGGAAAGTCTTCACCTATTGTCCTG 
GGGTCATTTCCCTAAAAAAGGTCC 
58 
g.SMC1A-18F 
g.SMC1A-18R 
TGGGTCTCACCTAGCCCCTG 
TTCATCGCCCACTCCCAC 
58 
g.SMCA1-19F 
g.SMCA1-19R 
CTGCTCCACTTGACTCTCCGT 
GAAGATAGTCCCACTCCCACC 
58 
g.SMC1A-20F 
g.SMC1A-20R 
CAGGCCCTTCTTGACATTGC 
TTGTCCTCATCGTAGGCCC 
58 
g.SMC1A-21F 
g.SMC1A-21R 
AGGTCCTTCTTGCCAGGGC 
GACAACTGAGGATGGTAGCAGC 
58 
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g.SMC1A-22F 
g.SMC1A-22R 
TCCCTATCTCCATCCAGTCTCAG 
AGTCTCTTCGTCAACTGCCCTAG 
58 
g.SMC1A-23F 
g.SMC1A-23R 
TGGCCTGTTTGATGGGCC 
AACCCAACCCCGACCTGG 
58 
g.SMC1A-24F 
g.SMC1A-24R 
TGCCTTCTGGTTGTGGCTG 
CAGGGAGTAGGACTGGCTCC 
58 
g.SMC1A-25F 
g.SMC1A-25R 
AGGGAGGAGGGTTTGAGGC 
CAGAGATTGGGAGAGGGACAG 
58 
 
